The clinical trials showed that immunotherapies targeting the PD-1/PD-L1 axis have a promising response (~45%) and can significantly prolong the survival of metastatic NSCLC patients [9,10]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.